As gene-modified cell therapy programs move into later-stage development, maintaining continuity across plasmid design and manufacturing becomes increasingly critical. Challenges at Phase II ...

Platform has the capability to reduce time from process development to GMP by 55 percent and deliver a drug product in fewer than 8 months nAAVigation platform will be launched at the Cell & Gene ...

Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network ...